Lynch syndrome (LS) is the most common cause of inherited colorectal cancer, a disease with a high mortality rate. An estimated 37,000 of diagnosed colorectal cancer cases worldwide are attributed to Lynch syndrome each year. Intensive cancer screening, with early initiation and frequent follow-up, can reduce colorectal cancer incidence and mortality in LS patients. This book provides an up-to-date overview on the genetic and epigenetic basis of Lynch syndrome. It evaluates clinical features of the disease and critically comments on molecular tools available for identifying mutations responsible for Lynch syndrome; in addition the importance of functional assays that can help clarify the clinical nature of identified mutations is also discussed. The book also focuses on challenges in genetic counselling of at-risk individuals and discusses related ethical issues. The purpose of the book is to give a concise knowledge base for the broader scientific and medical community, including genetic counselors, in order to improve awareness on the potential impact that the diagnosis of LS has on treatment, management and surveillance of LS patients.

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP in cancer therapy. The volume covers the history of the discovery of PARP (poly ADP ribose polymerase) and its role in DNA repair. In addition, a description of discovery of the PARP family, and other DNA maintenance-associated PARPs will also be discussed. The volume also features a section on accessible chemistry behind the development of inhibitors. PARP inhibitors are a group of pharmacological inhibitors that are a particularly good target for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA damaging agents used to treat cancer. Researchers have learned a tremendous amount about the biology of PARP and how tumour-specific defects in DNA repair can be exploited by PARPi. The "synthetic lethality" of PARPi is an exciting concept for cancer therapy and has led to a heightened activity in this area.

The contents of this book will be organized into three sections. The first section defines the scope, impact and behaviour of cancer regimen-related toxicities and frames the issue of balancing treatment success and physiological cost. In the second segment of the book, the most current thinking around the pathobiology of specific, common, and representative toxicities is presented by leading researchers and translational scientists. The final portion of the book discusses the common biological relationships between toxicities, bioinformatical approaches to analysing key and common pathways, and strategies for the development of effective interventions.

This book provides a state-of-the-art approach to the molecular basis of hematologic diseases and its translation into improved diagnostics and novel therapeutic strategies. Several representative hemato-oncologic malignancies are analyzed in detail: acute lymphoblastic leukemia, acute myeloid leukemia, B-cell Non-Hodgkin lymphomas, multiple myeloma, chronic lymphocytic leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Experts in the field describe the molecular methods applied for modern diagnostics and therapies, such as hematopoietic stem cell transplantation, donor recipient matching, banking of biological material, analyses of post-transplant chimerism, and minimal residual disease monitoring. The volume concludes with an extensive section comprising thorough step-by-step protocols of molecular techniques in hematology, all of them validated in the authors' own laboratories.

This book covers the scope of current knowledge of cancer in the LGBT community across the entire cancer continuum, from understanding risk and prevention strategies in LGBT groups, across issues of diagnosis and treatment of LGBT patients, to unique aspects of survivorship and death and dying in these communities. Each chapter includes an in depth analysis of the state of the science, discusses the many remaining challenges and unanswered questions and makes recommendations for research, policy and programmatic strategies required to address these. Focus is also placed on the diversity of the LGBT communities. Issues that are unique to cancer in LGBT populations are addressed including the social, economic and cultural factors that affect cancer risk behaviors, barriers to screening, utilization of health care services, and legislation that directly impacts the health care of LGBT patients, healthcare settings that are heterosexist and unique aspects of patient-provider relationships such as disclosure of sexual orientation and the need for inclusion of expanded definition of family to include families of choice. The implications of policy change, its impact on healthcare for LGBT patients are highlighted, as are the remaining challenges that need to be addressed. A roadmap for LGBT cancer prevention, detection, diagnosis, survivorship, including treatment and end of life care is offered for future researchers, policy makers, advocates and health care providers.

This book aims to provide an up-to-date review of the literature in each of the major areas relating to the management of older gynecological cancer patients, and makes recommendations for best practice and future research. The authors come from a broad geographic spread including the UK, mainland Europe and North America to ensure a worldwide relevance.

This book provides a detailed, intimate portrait of a community of women living in a shantytown (favela) in northeastern Brazil, while exploring the complex interplay between gender, sexuality, power, and disease. It reveals how poor Brasileiras are constrained by dominant cultural constructions of female sexuality as a dangerous force that must be controlled by men; yet these women also manipulate these expectations by using their sexuality as a means to secure economic support from men. The book argues that these constructions affect their interpretations of medical discourse on the prevention of cervical cancer. Since women view sex as both a force they can't control and as a necessary tool for their survival, they choose to de-emphasize medical warnings against risky sexual behavior, with grave consequences for their health. The text is threaded with poignant, humorous, sometimes graphic, and always memorable depictions of the women's lives in the shantytowns, making this serious anthropological study a highly readable one as well.

Multiple myeloma is a plasma cell malignancy characterized by complex heterogenous cytogenetic abnormalities that accounts for 1.4% of all cancers, and approximately 10% of hematologic malignancies. The clinical manifestations of multiple myeloma include lytic bone lesions, cytopenia, hypercalcemia, renal dysfunction, hyperviscosity of the blood, immunodeficiency, and peripheral neuropathy. Based on the clinical and genetic data, probably all cases of multiple myeloma arise from an asymptomatic monoclonal gammopathy of unknown significance. The exact mechanism of the transition from MGUS to overt multiple myeloma is still not well understood. Recent oncogenomic studies have further advanced our understanding of the molecular pathogenesis of multiple myeloma. This book will give a comprehensive overview of the genetic and molecular epidemiology of multiple myeloma in order to get a more refined and conclusive understanding of this disease.

Metastatic disease is the most lethal aspect of human malignancies, making the understanding and continued research of the process of metastasis a crucial step in treating cancer. The proposed book, entitled "Experimental and Clinical Metastasis: A Comprehensive Review" aims to provide a clear and extensive review of the clinical and experimental implications of metastatic disease. This work focuses on recent contributions to the field of metastasis, and will highlight crucial findings in the molecular understanding of disseminated disease as well as standard and personalized medicine currently being investigated in the clinic. Topics will include, among many, gene properties of metastatic cells, molecular mechanisms of tumour growth and spread, animal models of metastasis, and clinical implications, markers and treatment for metastatic disease. With the participation of worldwide experts in the field of oncology, from major academic and government centres, this book will provide a leading manual for the study of the metastatic process, from benchside science to bedside care. In this light, the proposed book will facilitate classroom learning for both medical and graduate students, as well as serve as a tool for physicians and researchers interested in the metastatic process. In addition, this book will include the latest advances in basic science as well as leading technologies and theories of targeting metastatic cells. Most importantly, not only will basic and clinical aspects be discussed, but furthermore, the translational aspect of research in metastatic diseases will be emphasized.

This volume provides insight into recent developments on experimental and clinical strategies for cancer gene therapy. Gene Therapy of Solid Cancers: Methods and Protocols guides readers through protocols on gene therapeutic strategies in combination with helpful technical notes. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Concise and easy-to-use, Gene Therapy of Solid Cancers: Methods and Protocols aims to ensure successful results in the further study of this vital field.

In recent years there have been various discoveries connecting inflammation and lung cancer and clearly there is growing interest in this area of cancer research. The link between unresolved inflammation and cancer has been well established with estimates that 15% of cancer deaths are inflammation-related. Evidence for this link includes the following: a) some inflammatory diseases are associated with increased risk of cancer development; b) inflammatory mediators are present surrounding and within most tumors; c) overexpression of inflammatory cytokines increases cancer development and progression in murine studies; d) inhibition of inflammatory mediators decreases cancer development and progression; and e) the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been found to decrease cancer incidence and delay progression. The volume will present aspects of the inflammatory tumor microenvironment (TME), its many roles in tumor progression and metastasis, including creation of a hypoxic environment, increased angiogenesis and invasion, changes in expression of micro-RNAs (miRNAs) and an increase in a stem cell phenotype. The book will also cover the mechanisms of inflammatory mediators. Chronic overexpression of inflammatory mediators in the TME, as seen in smokers and patients with non-small cell lung cancer (NSCLC), can also lead to increased tumor initiation, progression, invasion and metastasis. The volume will provide a comprehensive perspective of the latest findings and summaries of progress made regarding inflammation and its connection to lung cancer.

This book is a timely textbook that covers all aspects of neuroendocrine tumors (NET) from epidemiology, pathological classification and evaluation and molecular biology through to diagnostic imaging methods and therapeutic options, including the latest targeted therapies. The various types of NET are individually discussed, including carcinoid tumors, insulinomas, gastrinomas, glucagonomas, VIPomas, somatostatinomas, PPomas, medullary thyroid carcinomas, adrenocortical cancer, pheochromocytomas, paragangliomas and non-functioning pancreatic NETs. The contributing authors are internationally recognized experts who bring a wealth of experience to the subject. This book will be an invaluable source of information for practicing medical oncologists, surgeons, endocrinologists, gastroenterologists and pathologists and also trainees.

Hamed Alborzinia uses the biosensor chip to monitor the metabolic and morphological changes in cancer cell lines in real time, particularly: (i) real-time measurements of basic cancer cell metabolism of different cancer cell lines; (ii) a detailed timeline of the metabolic response to cisplatin treatment and clear detection of the time span between start of cisplatin treatment and onset of cell death, which reflects the time required for the underlying molecular mechanisms of cell fate decision; (iii) direct functional measurement of the biological activity of a key regulatory protein of cellular metabolism following the kinetic change in respiration upon SIRT3 overexpression; and (iv) the time-resolved impact of several organometallic compounds on cell metabolism and cell morphology, including unexpected and not yet understood highly significant and specific effects on cell-cell interaction and adhesion.

This book is designed for clinical cardiologists and other physicians working with cardiac patients, where specific specialized teams of cardio-oncologists are not available and who are called to perform a clinical consultation to evaluate both the cardiac condition and the eligibility for chemotherapy or radiotherapy treatment, and to evaluate if a cancer treatment produces toxic effects on a patient treated with chemo or radiotherapy and if appearance of new symptoms is due to this treatment. In recent years, progress in oncologic therapy has resulted in important developments and the prognostic improvement of patients with malignancy. The cornerstone of chemotherapy are the anthracyclines (and the analogue Mitoxantrone), that are direct cellular toxic agents and that are among the most powerful anti-neoplastic drugs, but their cardiac toxicity is well known. Significant breakthroughs in cancer therapy have also been achieved with the introduction of signalling inhibitors, such as VEGF inhibitors, HERB2 inhibitors or TK inhibitors used alone or in combination with direct cellular toxic drugs. However, these signalling inhibitors may interact also with cardiovascular signalling and therefore may have functional or structural effects on the myocardium. This can be permanent or reversible, with impairment of the global conditions and important side effects, and increase both morbidity and mortality and worsening of quality of life. Chemotherapy and radiotherapy can have acute detrimental effects that can be present for years after treatment and that can lead to cardiac consequences also after long periods of no clinic sequelae. Patient numbers with cancer problems will dramatically increase in the next years and thus every cardiologist will need to have the correct information and the skills to manage these situations in the correct way. This book will provide these tools for them.

The identification of normal and breast cancer stem cells has offered a new vision of this heterogeneous disease and new hopes for its prognosis and treatment. This volume provides an overview of recent developments in mammary stem cell research and discusses the many varieties of approaches used by researchers to investigate the properties and functions of mammary stem cells. The beginning chapters provide readers with an introduction to mammary stem cells, and the processes used to characterize stem cells and isolate them via fluorescent activated cell sorting. The next few chapters discuss DNA and mRNA sequencing, proteomic techniques to help profile cells, lentiviral cell transduction for gene expression, and in vivo lineage tracing. The final few chapters are dedicated to following stem cells from their initial niche to the new microenvironment at their metastasis site, and to studying these cells using physical and mathematical approaches. Written in the highly successful Methods in Molecular Biology series format, the chapters include the kind of detailed description and implementation advice that is crucial for getting optimal results in the laboratory. Authoritative and cutting-edge, Mammary Stem Cells: Methods and Protocols aims to help members of the scientific community explore the behavior of stem cells and how to work with them in order to guide the design of new and complimentary strategies to be applied in the clinic with the ultimate end goal of fighting breast cancer.

Advances in Nitric Oxide and Cancer is a volume that serves to give the latest research on nitric oxide (NO) and cancer. More specifically, the volume reviews significant advances in the application of NO-mediated drugs. The volume explores nitric oxide and its relationship to cancer spanning from its roles in the pathogenesis, prognosis, gene and protein modifications, regulation of resistance to cytotoxics, and therapeutic applications. With chapters written by leading experts, the volume addresses the burgeoning interest in a rapidly advancing field and provides a valuable resource to scientists who have initiated research as well as clinical investigations in their laboratories on the various roles of NO and cancer.

The authors aim to provide essential information on various clinical cases on urological cancers. The main messages are well referenced and the texts phrasing is written in a simple and user-friendly style. The book also contains summarizing tables and high quality original pictures. Several expert panels (American Urologists Association, European Association of Urologists, Association Francaise des Urologues, etc) are proposing guidelines aiming at providing detailed recommendations to the Urologists facing difficult urological scenarios and no significant discordance exist between them since they are all based on the existing published studies dealing with different aspects of the urological cancers.

Endocytosis and vesicular trafficking determine the landscape of the cell's exterior, namely the density of surface molecules, such as receptors for growth factors and cytokines, adhesion molecules like integrins and cadherins, and a plethora of nutrient carriers. Hence, endocytosis is involved in signal transduction, cell adhesion and migration, as well as metabolism. To exploit these fundamental processes, malignancies subtly and multiply manipulate the endocytosis and the subsequent trafficking of protein cargoes. This is achieved by simultaneously altering the cytoskeleton, vesicle budding, cargo sorting and intracellular degradation. By highlighting the underlying molecular processes and concentrating on specific examples, this book reviews the recent emergence of derailed endocytosis and vesicular trafficking as a landmark of cancer. In-depth understanding of this common feature of tumors might lead the way to drug-induced strategies, able to rectify intracellular trafficking in cancer.

Georg Stuebinger verifies each of the 24 most common and deadliest cancer diseases worldwide including well-established and potential risk factors resp. important symptoms by using current literature and comprehensive scientific studies with a direct relation to the impact of various parameters of sports and exercise training such as training type, intensity, volume, duration and frequency complete with the corresponding effects. The impact of sports and exercise training as a potential therapy on reduced risk of cancer has been widely discussed in many scientific articles over the last few years, but is still widely unknown. In 2012, about 14 m cancer cases and 8.2 m cancer deaths appeared worldwide whereby cancer represents one of the most frequent causes of death accounting for approximately 13% with a continuously rising number.

Sphingolipids are lipid components of the plasma membrane of eukaryotic cells with an important function in signaling mechanisms in the cell. This book provides insight into the physiological and pathophysiological role of sphingolipids and in particular its derivative ceramide. The function of Sphingolipids in cell signaling with regard to infectious and lung diseases, cancer, cardiovascular diseases and neuropsychiatric disorders are described and treated in distinct parts. Together with Volume 215 from the same Editors, the collection represents a unique, comprehensive work on Sphingolipids, providing information on both: Sphingolipid basic biology as well as its important function in a (patho)physiological context. The book is written for scientists in pharmacology, biochemistry and cell biology with a focus on biomedical research as well as for clinicians in pharmacology, oncology, cardiology, neurology and infectious disease.

Cancer is one of the leading killers in the world and the incidence is increasing, but most cancer patients and cancer survivors suffer much from the disease and its conventional treatments' side effects. In the past, clinical data showed that some complementary and alternative medicine (CAM) possessed anticancer abilities, but some clinicians and scientists have queried about the scientific validity of CAM due to the lack of scientific evidence. There is great demand in the knowledge gap to explore the scientific and evidence-based knowledge of CAM in the anticancer field. With this aim, a book series is needed to structurally deliver the knowledge to readers. Throughout the past few years, the cancer chemopreventive potencies and treatment effects of a number of natural dietary agents present in different food sources have been evaluated by various experiments. Some of them have progressed to early clinical trials. This volume is a specialized book presenting the research evidence relevant to the use of specific diet therapy in cancer chemoprevention and treatment. We begin with lessons learned from dietary resveratrol as an effective agent with anticancer properties against malignancies, followed examples of flavonoids from fruits and vegetables in the prevention and treatment of cancer. Evidence for the beneficial influence of diet enriched with flax seed oil and green tea on cancer will be reviewed. Soy food intake may enhance the effects on anticancer treatment for breast cancer, whereas lycopene-rich foods may possess chemopreventive efficacy. There are also discussions on the contribution of the cancer preventive effects of the antioxidant-rich foods and Mediterranean diet. In addition, the modulation of proteasome pathways by nutraceuticals is highlighted. Finally, we close the book with a discussion on the attenuation of cell survival signaling by bioactive phytochemicals in the prevention and therapy cancer.

Pancreatic cancer is a formidable disease, and advances in early detection and improved therapeutics have been slow to come forth. With new advances in molecular genetics in the field of pancreatic tumorigenesis, it is an opportune time to use these recent discoveries to enhance our understanding of pancreatic cancer biology and to improve outcomes in patients. In this volume, leading experts in the field shed light on these findings describing the mutational landscape of pancreatic cancer, including new inroads into our understanding of familial pancreatic cancer, epidemiology, the biology of K-ras signaling, and the emerging contribution of epigenetic alterations to disease initiation and progression. The distinctive pancreatic cancer-stroma ecosystem as determined by the dynamic interplay of inflammation, hallmark mutations, EMT, and cancer stem cells is described, and implications of these interactions in the context of development of novel, personalized therapeutic options are explored.

This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.

Latest generation sequencing revolutionizes the fields of cancer research and oncology. This follow-up volume focuses more extensively on single cell sequencing of cancer and trials in drug resistance. Another exciting feature is the bioinformatics tools given, that can be used on cancer genome studies. Scientists around the world are attempting to find the root cause of cancer. A reasonable cancer treatment plan and potential cure is more optimistic now with the unfolding of the cancer genome. The collective knowledge of how to leverage next generation sequencing in cancer research is paving the way. The important information provided in this volume will move the field forward in developing novel targeted cancer therapies.

This book discusses emerging nanotechnology-based tools that have the potential to dramatically impact cancer research, diagnostics, and treatment. Cancer is a complex, devastating, and debilitating disease and, although much progress has been made, novel, more effective diagnostic and treatment options are still needed, especially for advanced cancers. The ultimate goal is to detect cancer early and non-invasively and to provide efficacious and targeted precision treatments that cause fewer harmful side effects. This book explains how nanotechnology can exploit the size-, shape-, and composition-dependent properties of nanomaterials to provide novel tools for precision cancer medicine. It will be of interest to researchers and professionals working in the fields of chemistry, biology, materials science and engineering, and medicine who want to learn more about this fascinating and fast-paced area of research.